Fig. 1: Possible sequencing of novel therapies for patients with RR CLL independent of prior chemoimmunotherapy. | Blood Cancer Journal

Fig. 1: Possible sequencing of novel therapies for patients with RR CLL independent of prior chemoimmunotherapy.

From: Update on the management of relapsed/refractory chronic lymphocytic leukemia

Fig. 1

*In event of intolerance, a second cBTKi may be considered initially if appropriate. $Current approvals for Pirto are restricted to BTKi- and BCL2i-exposed patients. BCL2iB-cell lymphoma-2 inhibitor, cBTKi covalent Bruton’s tyrosine kinase inhibitor, mAb monoclonal antibody, ncBTKi non-covalent BTKi.

Back to article page